Publication | Open Access

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

First-line TherapyMedicinePharmacologyAnti-cancer AgentPhase-i/ii StudyCancer TreatmentOncologyRadiation OncologyLung Cancer